Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Elizabeth A Spencer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics Mount Sinai, Icahn School of Medicine, 17 E. 102nd Street, Fifth Floor…. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Colitis, Ulcerative. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH.
Abstract (Originalsprache)
Background
Upadacitinib (UPA) is a novel selective JAK inhibitor approved for adults with ulcerative colitis (UC) and with positive phase 3 data for Crohn’s disease (CD). Pediatric off-label use is common due to delays in pediatric approvals; real-world data on UPA are needed to understand the safety and effectiveness in pediatric IBD.
Methods
This is a single-center retrospective case series study of adolescents (12-17 years) with inflammatory bowel disease IBD on UPA. The primary outcome was postinduction steroid-free clinical remission (SF-CR) defined as Pediatric UC Activity Index (PUCAI) or Pediatric CD Activity Index (PCDAI) ≤10. Secondary outcomes include postinduction clinical response (decrease ≥12.5 in PUCAI/PCDAI), postinduction C-reactive protein (CRP) normalization, 6-month SF-CR, and intestinal ultrasound response and remission. Adverse events were recorded through last follow-up.
Results
Twenty patients (9 CD, 10 UC, 1 IBD-U; 55% female; median age 15 years, 90% ≥2 biologics) were treated with UPA for ≥12 weeks (median 51 [43-63] weeks). Upadacitinib was used as monotherapy in 55% and as combination with ustekinumab and vedolizumab in 35% and 10%, respectively. Week 12 SF-CR was achieved in 75% (15/20) and 80% (16/20) with CRP normalization. About 3/4 (14/19) achieved SF-CR at 6 months. Adverse event occurred in 2 patients (10%): Cytomegalovirus colitis requiring hospitalization and hyperlipidemia requiring no treatment. In the 75% with ultrasound monitoring, response and remission were achieved in 77% and 60%, respectively.
Conclusion
While awaiting pediatric registration trials, our data suggest that UPA is effective in inducing and maintaining SF-CR in adolescents with highly-refractory IBD with an acceptable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics Mount Sinai, Icahn School of Medicine, 17 E. 102nd Street, Fifth Floor, New York, NY, 10029, USA.
ORCID-Profile: Elizabeth A Spencer, Michael Dolinger, David Dunkin
Förderung
- NIDDK NIH HHS
- NIH
Zitieren
APA
Spencer, E. A., Bergstein, S., Dolinger, M., Pittman, N., Kellar, A., Dunkin, D., & Dubinsky, M. C. (2024). Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad300
Vancouver
Spencer EA, Bergstein S, Dolinger M, Pittman N, Kellar A, Dunkin D, et al. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad300
BibTeX
@article{Spencer2024,
author = {Spencer, Elizabeth A and Bergstein, Suzannah and Dolinger, Michael and Pittman, Nanci and Kellar, Amelia and Dunkin, David and Dubinsky, Marla C},
title = {Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad300}
}
EUVIMED